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ABSTRACT 
Background: Growth Differentiation Factor 15 (GDF-15) is a cytokine produced in response to 
tissue injury and inflammatory states that may capture distinct pathways between the risk factors 
aggregated within metabolic syndrome (MS) and the development of diabetes and cardiovascular 
disease. 
Objective: To study the association of MS and its components with GDF-15 among older adults, 
examining the roles of body fat distribution, glucose metabolism, and inflammation. 
Methods: Data were taken from the Seniors-ENRICA-2 study in Spain, which included 1938 
non-institutionalized individuals aged ≥65 years free of diabetes and cardiovascular disease. MS 
was defined as the presence of ≥3 of the following components: high waist circumference, 
elevated fasting blood glucose levels, raised blood pressure, increased triglyceride levels; and low 
serum high-density lipoprotein (HDL) cholesterol. Statistical analyses were performed with linear 
regression models and adjusted for potential sociodemographic and lifestyle confounders. 
Results: MS was associated with higher GDF-15 levels (fully adjusted mean increase [95% 
confidence interval] = 9.34% [5.16,13.7]). The MS components showing the strongest 
associations were high waist circumference (6.74% [2.97,10.6]), elevated glucose levels (4.91% 
[0.77,9.23]), and low HDL-cholesterol (8.13% [3.51,13.0]). High waist-to-hip ratio (7.07% 
[2.63,11.7]), urine albumin (12.1% [2.57,22.5]), and C-reactive protein (10.4% [3.89,17.3]) were 
also associated with increased GDF-15. 
Conclusion: MS was associated with higher GDF-15 levels in older adults. Abdominal obesity, 
hyperglycemia -possibly linked to microvascular disease, as inferred from elevated urine 
albumin-, low HDL-cholesterol, and inflammation were the main drivers of this association. 
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INTRODUCTION 
Metabolic syndrome (MS) is a cluster of five cardiometabolic risk factors comprising abdominal 
obesity and abnormal blood pressure, blood glucose, triglycerides, and high-density lipoprotein 
(HDL) cholesterol. MS has been advocated as a simple clinical tool for predicting type 2 diabetes 
and cardiovascular disease, as it increases the risk for the former fivefold and doubles the risk for 
the latter [1–3]. Several pathophysiological links between the metabolic risk factors aggregated 
within MS and the development of diabetes and cardiovascular disease have been proposed [2–
4]. First, insulin resistance is the primary cause of hyperglycemia, whose most relevant clinical 
outcome is microvascular disease, manifested as neuropathy and nephropathy. Insulin resistance 
may also be linked with hypertension through increased renal reabsorption of sodium leading to 
an expansion of intravascular volume, further accelerating the development of heart failure and 
atherosclerosis. Second, high levels of triglycerides and reduced HDL cholesterol, jointly with 
elevated low-density lipoproteins, seem to be the main cause of atherosclerotic cardiovascular 
disease. Finally, adipose tissue is associated with: 1) insulin resistance via the supply of ectopic 
fat to muscle and pancreas; 2) hypertension through activation of the renin-angiotensin-
aldosterone and sympathetic nervous systems; and 3) insulin resistance, hypertension, and 
atherosclerosis via the production of inflammatory adipokines and other bioactive peptides [2–5]. 
In this regard, Growth Differentiation Factor 15 (GDF-15) is a cytokine produced in response to 
tissue injury and inflammatory states by cardiomyocytes, adipocytes, macrophages, endothelial 
cells, and vascular smooth muscle cells, where it plays a tissue-protective role through up- and 
downregulation of several signaling pathways [6,7]. Higher serum GDF-15 concentrations may 
be a clinically relevant biomarker within the context of MS, as they have been associated with 
several MS components [6,8,9] and with the development and progression of cardiovascular and 
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diabetes-related conditions, specifically cardiac hypertrophy, heart failure, atherosclerosis, 
endothelial dysfunction, insulin resistance, diabetes, and chronic kidney disease, as well as with 
cardiovascular and all-cause mortality [6,7]. Nevertheless, little is known about the association of 
MS with GDF-15 in older adults and its main drivers [8,10], and it is uncertain if they are related 
to alterations in glucose metabolism, inflammation, or both. Moreover, these assessments might 
render different results than in younger populations [8,11], as both MS prevalence and GDF-15 
levels are consistently higher in the elderly than in younger subjects [7,12–14]. Furthermore, 
despite being an adipokine, it is unclear whether GDF-15 is associated with abdominal fat -that 
clustered within MS-, gluteofemoral fat, or overall adiposity [7,8]. 
We hence aimed to 1) assess the association of MS and its components with GDF-15 in 
community-dwelling older adults and 2) delve into these relationships by examining the 
associations of ancillary adiposity measures (body mass index, hip circumference, and waist-to-
hip ratio) and auxiliary metabolic biomarkers (Homeostatic Model Assessment for Insulin 
Resistance [HOMA-IR], glycated hemoglobin, urine albumin, and high-sensitivity C-reactive 
protein [hs-CRP]) with GDF-15. 
METHODS 
Study design, setting, and participants 
Our data came from the baseline wave of the Seniors-ENRICA-2, a cohort study on 
cardiovascular health, nutrition, and physical functioning in older adults in Spain 
(ClinicalTrials.gov Identifier: NCT01133093) [15,16]. Subjects were recruited between 
December 2015 and June 2017 by sex- and district-stratified random sampling of the community-
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dwelling, 65-years and older national healthcare cardholders living in the city of Madrid (Spain) 
or four surrounding large towns: Getafe, Torrejón, Alcorcón, and Alcalá de Henares. 
The study methods were analogous to those of the Seniors-ENRICA-1 cohort, which have been 
detailed elsewhere [17]. In brief, a comprehensive set of physical examinations, blood, and urine 
tests were collected during two home visits by trained personnel, whereas data on socio-
demographic, lifestyle, and morbidity variables were gathered through a telephone interview 
[17]. All subjects gave written informed consent, and the Clinical Research Ethics Committee of 
the “La Paz” University Hospital in Madrid approved the research protocol. 
Variables, data sources, and measurements 
GDF-15 
Fasting blood samples were obtained from every subject at the first home visit in rapid serum 
tubes with a thrombin-based clot activator and polymer gel (Becton Dickinson). Tubes were 
centrifuged at 3000 rpm for 10 minutes and serum was aliquoted and stored at -80ºC in the 
Department of Preventive Medicine and Public Health at Universidad Autónoma de Madrid. 
Serum GDF-15 was quantified at the Department of Laboratory Medicine of “La Paz” University 
Hospital by an electrochemiluminescence Elecsys® immunoassay method using a cobas® 6000 
analyzer (Roche Diagnostics). The inter-assay coefficient of variation was 5.4% for a mean 
concentration of 7343 pg/mL and 7.7% for 1428 pg/mL. 
Metabolic syndrome 
Waist circumference was measured by trained staff with a flexible, inelastic, belt-type tape at the 
midpoint between the lowermost rib and the iliac crest at the end of a normal expiration [18]. 
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Blood pressure was determined three times under standardized conditions with validated 
automatic sphygmomanometers (Mobil-O-Graph® 24h PWA, I.E.M., Stolberg, Germany), and 
the mean of the 2nd and 3rd assessments was used in the analyses [19]. 12-hour fasting serum 
glucose, triglycerides, and HDL-cholesterol were measured with colorimetric enzymatic methods 
using Atellica® solution (Siemens Healthineers). 
MS was defined as the presence of ≥3 of the following 5 components: a waist circumference 
≥102 cm in men and ≥88 cm in women; fasting blood glucose ≥100 mg/dl or drug treatment of 
hyperglycemia; a systolic blood pressure ≥130, a diastolic blood pressure ≥85 mm Hg, or being 
on antihypertensive drug treatment; serum triglycerides ≥150 mg/dl; and serum HDL-cholesterol 
<40 mg/dl in men or <50 mg/dl in women [1]. Since it has been argued that MS is a pre-morbid 
condition rather than a clinical diagnosis [2], we excluded individuals with self-reported 
cardiovascular disease (myocardial infarction, stroke, or heart failure) or established diabetes 
(blood glucose ≥126 mg/dL, HbA1c ≥6.5 %, being treated with antidiabetic drugs, or self-
reported diagnosis of diabetes mellitus). 
Ancillary adiposity measures 
To further investigate the association between body fat and GDF-15, we used data on three 
additional adiposity measures. First, body mass index (BMI) was calculated as weight (in kg) 
divided by squared height (in m). Weight and height measurements were conducted under 
standardized conditions using electronic scales and portable extendable stadiometers, respectively 
[18]. Normal weight was considered as BMI <25, overweight as BMI 25–29.9, and obesity as 
BMI ≥30 kg/m2. Hip circumference was measured by trained staff with a flexible, non-
distensible, belt-type tape on the maximum circumference over the femoral trochanters; for 
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analyses, hip circumference was divided into sex-specific tertiles (cutoffs at 98 and 104 cm in 
men, and 99.6 and 107 cm in women). The waist-to-hip ratio was computed as waist 
circumference (in cm) divided by hip circumference (in cm). Cutoff values of ≥0.90 in men and 
≥0.85 in women were used, for they have been associated with a substantially increased risk of 
metabolic complications [20]. 
Ancillary metabolic biomarkers 
To explore in more depth the relationship between glucose metabolism and GDF-15 levels, we 
first measured 12-h fasting serum insulin through a chemiluminescent immunoassay using 
Atellica® solution (Siemens Healthineers) and calculated the HOMA-IR as blood glucose (in 
mg/dl) multiplied by serum insulin (in mU/l) and further divided by 405 [21]. We used cutoff 
values of ≥2.25 in men and ≥2.38 in women, as they have demonstrated a 70% specificity in MS 
classification in older adults [22]. Second, we determined glycated hemoglobin (HbA1c) using 
high-performance liquid chromatography with Arkray Adams™ A1c HA-8180 (Menarini). The 
threshold level for prediabetes was set at ≥5.7 % [23]. We finally measured albumin excretion in 
spot urine, as an early predictor of progressive renal function loss in prediabetes and diabetes, 
through the immunoturbidimetry technique using Atellica® solution (Siemens Healthineers). 
Urinary albumin excretions <10, 10-20, and ≥20 mg/l were considered normal, high normal, and 
microalbuminuria, respectively [24]. 
As a marker of inflammation, we also determined hs-CRP levels using the abovementioned 
immunoturbidimetry technique. Cutoff points were set at 1.0 mg/l and 3.0 mg/dl, according to 
relative risk categories of cardiovascular disease [25]. 
Potential confounders 
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We used data on several self-reported potential confounders of the association between MS and 
GDF-15, specifically sex, age, educational level (primary or less, secondary, or university), 
smoking status (never, former, or current), and alcohol consumption (never, former, moderate 
[≤10 g/day in women and ≤20 g/day in men], or heavy). Physical activity time (min/day) was 
assessed with an ActiGraph GT9X (ActiGraph Inc) accelerometer. Intensity thresholds were set 
at <45 miligravitational units (mg) for sedentary behavior, ≥45 and <100 mg for light physical 
activity, and ≥100 mg for moderate-to-vigorous physical activity [16]. When not available, we 
used self-reported data on sedentary behavior and physical activity instead [26,27]. Dietary 
information, including energy intake (kcal/day), was obtained from a validated diet history [28]. 
Diet quality was assessed with the Mediterranean Diet Adherence Screener (MEDAS), with 
higher scores indicating better adherence to the Mediterranean diet [29]. 
Statistical Methods 
Study size 
From the 3273 individuals recruited in the study (51% of those invited), we excluded 758 with 
inadequate data (719 subjects had incomplete information on MS or ancillary adiposity measures, 
684 on GDF-15, and 488 on potential confounders; note that one individual may lack data in 
more than one variable). We also excluded 577 individuals with established diabetes or known 
cardiovascular disease. Hence, the main analytical sample comprised 1938 individuals. For the 
analyses regarding ancillary metabolic biomarkers, we excluded another 1085 participants 
without data on HOMA-IR, glycated hemoglobin, urine albumin, or hs-CRP. Thus, this 
secondary analytical sample included 853 subjects (Supplemental Figure 1). 
Statistical methods 
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Differences in characteristics of study participants across the categories of MS and its 
components were evaluated with Pearson's chi-squared tests for discrete variables and Wilcoxon 
rank-sum tests for continuous variables. 
Main analyses were conducted with linear regression models where the outcome was log-
transformed GDF-15, as a continuous variable, and exposures were MS or its components, as 
dichotomous variables. We calculated GDF-15 mean percentage differences and their 95% 
confidence interval (CI) between the subjects with and without MS and each of its components. 
This was done by taking 1 from the exponentiated β coefficients in the regression models and 
multiplying the result by 100. Dose-response relationships were assessed by restricted cubic 
spline regression. To control for potential confounding, two a priori hierarchical models were 
used: 1) adjusted for sociodemographic characteristics (age, sex, and educational level), and 2) 
additionally adjusted for lifestyle variables (tobacco smoking, alcohol consumption, diet quality, 
energy intake, light physical activity, moderate-to-vigorous physical activity, and sedentary 
behavior). 
The associations of ancillary adiposity measures and metabolic biomarkers with GDF-15 were 
examined alike, except that we used tests for trend to check for dose-response relationships 
instead, modeling the median values per category as a single continuous variable. 
Statistical significance was set at a two-sided p-value <0.05. Analyses were performed with 
Stata® (StataCorp LLC), version 14. 
Missing data, interactions, and sensitivity analyses 
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Firstly, to investigate how incomplete data may have affected our findings, we compared the 
characteristics between participants who were and were not included in the analyses because of 
missing values on any variable of interest. Secondly, we tested whether the association of MS 
with GDF-15 differed in men and women, or subjects ≤70 and >70 years, as both MS prevalence 
and GDF-15 levels appear to steadily increase with age [7,12–14]. To do so, we used Wald tests 
that compared models with and without interaction terms, defined as the product of sex or the age 
subgroup by the dichotomous MS variable. Since no statistically significant interactions were 
found, results are presented for the total sample. Finally, to provide further insight on the dose-
response relationship between MS and GDF-15 at higher levels of its components -particularly 
fasting glucose-, we replicated the analyses without excluding individuals with established 
diabetes or known cardiovascular disease. 
RESULTS 
Descriptive data 
The prevalence of MS [95% CI] was 26.9% [25.0,28.9]. Subjects with MS were more likely to be 
women, slightly older, more sedentary, did less light and moderate-to-vigorous physical activity, 
and had a higher energy intake. Table 1 also shows a detailed distribution of each MS component 
by sociodemographic and lifestyle variables. 
Compared to participants included in the analyses, those with incomplete data had higher GDF-
15 levels (1389 vs 1124 pg/ml). They also were more likely to have MS (41.7 vs 26.9%), older 
(72.8 vs 71.4 years), less educated (68.1% vs 62.2% had primary or lower studies), more 
sedentary (1066 vs 783 min/day), did less moderate-to-vigorous physical activity (31.4 vs 61.2 
min/day), and had lower diet quality (6.91 vs 7.13 MEDAS scores). 
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Main results 
The geometric GDF-15 means [95% CI] were 1227 [1183,1272] and 1088 pg/ml [1065,1111] for 
participants with and without MS, respectively (mean percentage difference = 12.7% [8.17,17.5]) 
(Table 1, Table 2). This association remained when adjusting for sociodemographic (model 1 = 
11.4% [7.12,15.8]) and lifestyle variables (model 2 = 9.34% [5.16,13.7]), and it was dose-
dependent (Table 2, Figure 1). The components of MS that contributed the most to this finding 
were high waist circumference (model 2 mean percentage difference = 6.74% [2.97,10.6]), high 
glucose levels (4.91% [0.77,9.23]), and low HDL-cholesterol (8.13% [3.51,13.0]). Conversely, 
the associations of high blood pressure and triglycerides with GDF-15 were modest and did not 
reach statistical significance (1.49% [-2.55,5.69] and 2.54% [-2.04,7.34], respectively) (Table 2, 
Figure 1). 
Consistent with the findings for waist circumference alone, a high waist-to-hip ratio was 
associated with 7.07% [2.63,11.7] higher levels of GDF-15, even though there was little to no 
association for hip circumference alone (0.77% [-3.50,5.23]) and BMI ≥30 (2.38% [-2.47,7.48]) 
(Table 3). 
Regarding ancillary metabolic biomarkers, glycated hemoglobin ≥5.7% did not show an 
association with GDF-15 levels (-0.05% [-4.94,5.09]). Still, some trend was found for high 
HOMA-IR (3.13% [-1.91,8.43]), while participants with high urine albumin and hs-CRP 
concentrations did have higher GDF-15 levels (12.1% [2.57,22.5] and 10.4% [3.89,17.3], 
respectively) (Table 4). 
Other analyses 
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When including in the analyses the 577 participants with established diabetes or known 
cardiovascular disease, the strength of the association between MS and GDF-15 substantially 
increased (model 2 mean percentage difference = 24.3% [19.7,29.1]). So was the case for all the 
MS components, and even the associations with high blood pressure and triglycerides reached 
statistical significance. (Supplemental Table 1). Contrary to the analyses restricted to premorbid 
subjects, BMI ≥30 was significantly associated with increased GDF-15 levels (Supplemental 
Table 2), as were both glycated hemoglobin ≥5.7% and high HOMA-IR (Supplemental Table 3). 
DISCUSSION 
Key results 
In this study of older adults in Spain, MS was consistently associated with higher GDF-15 levels. 
The MS components that showed the strongest associations were high waist circumference, 
elevated glucose levels, and low serum HDL-cholesterol. Ancillary adiposity measures as the 
waist-to-hip ratio and auxiliary metabolic biomarkers as urine albumin and hs-CRP were also 
associated with increased GDF-15. 
Interpretation 
Our main results are in line with the few studies that have directly examined the association 
between MS and GDF-15. Specifically, in two cross-sectional studies (mean ages 80 and 59 
years), higher GDF-15 levels were associated with MS (≈2.6 greater odds and p<0.001, 
respectively) [10,30], whereas a small case-control study of obese subjects (mean age 34 years) 
found that patients with MS had ≈120% higher GDF-15 concentrations than otherwise healthy 
controls [11]. 
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Contrary to other investigations conducted in younger populations [31,32], we could hardly 
demonstrate a trend between BMI ≥30 and higher GDF-15, which only became apparent when 
including those subjects with diabetes or cardiovascular disease. It has been argued that the 
current BMI classification may not be appropriate in older adults, as overweight and even 
moderate obesity (BMI 24-33) do not seem to be associated with increased mortality in this age 
subgroup [33,34]. Anyway, since total body weight is primarily composed of both fat and muscle 
mass and only the former may be linked with higher GDF-15 concentrations, associations with 
BMI could be weaker than with other adiposity measures [8,35]. In this regard, the association 
between high waist circumference, waist-to-hip ratio, and GDF-15 found by us and others [8,31] 
-and the lack of it for hip circumference- may suggest that it is abdominal fat that mediates the 
corresponding association of obesity with GDF-15. Despite being a cytokine produced in 
response to adipose-tissue-driven inflammation (note that increased hs-CRP has been linked to 
both obesity and GDF-15 [30,36]), abdominal fat leads to a higher release of free fatty acids into 
circulation than gluteofemoral fat, which may be deposited in other tissues and organs or re-
esterified into triglycerides in the liver [3,37]. On one hand, GDF-15 could then be reflecting the 
mitochondrial dysfunction associated with ectopic fat accumulation in muscle [12]. On the other 
hand, both elevated triglyceride levels and reduced serum HDL-cholesterol -as part of 
atherogenic dyslipidemia- play a role in the initiation and development of atherosclerosis [3], 
which may, in turn, lead to a rise in GDF-15 levels, as suggested by the strong association of the 
latter with cardiovascular disease [6,7]. We and others have indeed found a link between serum 
HDL-cholesterol, triglycerides, and GDF-15 [8,30,35], though in our study the second was not 
statistically significant after adjustment for lifestyle variables. As for elevated blood pressure, its 
contribution to atherogenesis may exert some degree of tissue damage at a systemic level [3], 
though there is little -if any- evidence linking hypertension with GDF-15 concentrations [30,35]. 
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Another pillar of MS are alterations in glucose metabolism. As the primary cause of 
hyperglycemia in patients with MS, insulin resistance has traditionally been associated with 
higher levels of GDF-15 [31,35,38]. In our study, the magnitude of the estimates for HOMA-IR 
was rather smaller than for fasting glucose levels -both in main and sensitivity analyses-, waist 
circumference, and hs-CRP. Since obesity increases insulin requirements, imposes metabolic 
stress on pancreatic beta cells, and promotes cellular exhaustion via pro-inflammatory signals [5], 
part of the association between hyperglycemia and GDF-15 might not be mediated by insulin 
resistance. Moreover, since insulin resistance habitually precedes the rise in blood glucose levels 
(at the expense of compensatory hyperinsulinemia), it may be of particular relevance during the 
initial phases of MS [3]. However, in more advanced stages, such as those more likely 
represented in a prevalence study like ours, blood glucose may already be elevated, and hence the 
association of glycemia with GDF-15 might predominate over that with insulin resistance. 
A further discrepancy with other epidemiologic studies is that HbA1c was not associated with 
higher GDF-15 [35], contrary to fasting glucose levels. Any explanation must be conjectural, as 
subjects with altered single time-point glucose measurements likely have altered average 
glycemia as well [39]. However, HbA1c levels may rise with age beyond the expected elevations 
in fasting glucose, and the specificity of HbA1c-based diagnostic criteria for prediabetes might 
decrease with increasing age [40]. Accordingly, in our main analytical sample, the Pearson’s 
correlation coefficient between fasting glucose and HbA1c was low (r=0.39), yet doubled when 
including those subjects with established diabetes, in line with the observed substantial increase 
in the association of HbA1c with GDF-15 (Supplemental Table 3). 
Finally, microalbuminuria, being the primary clinical outcome of hyperglycemia [3,41], also was 
associated with elevated GDF-15 levels, in line with the robust evidence on the secretion of 
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GDF-15 in response to early endothelial and microvascular damage [8,42] and on its role as a risk 
marker of diabetic nephropathy [8,43]. 
Generalizability 
On one hand, the prevalence of MS found in our study might be lower than that in other settings 
and countries. For instance, 42.3% of the Spanish population ≥65 years [13] and 50.4% of adults 
≥60 years in the United States [14] have MS, compared to 36.3% of our participants -note that all 
figures comprise individuals with diabetes and cardiovascular disease-. Nevertheless, 1) Subjects 
included in our analyses met 0 to 5 MS criteria, while their ranges of waist circumference, fasting 
glucose, blood pressure, triglyceride, and serum HDL-cholesterol levels were also broad (Figure 
1); 2) The association of MS with GDF-15 was stronger when including in the analyses those 
subjects with diabetes and cardiovascular disease, who more frequently complied with ≥4 MS 
criteria and generally had higher levels of its components; and 3) The association between MS 
and GDF-15 showed a clear dose-response relationship with the number of MS criteria. So was 
the case for waist circumference, though some saturation seemed to arise at higher triglyceride 
and HDL-cholesterol levels (Figure 1). 
On the other hand, GDF-15 levels are reported to steadily increase with age [12,30,44] and our 
study comprised people ≥65 years. The mean serum GDF-15 concentration found in subjects 
without MS (1088 pg/ml) was consistent with that of other studies of healthy community-
dwelling older adults [44,45], but ≈60% higher than that observed in subjects 17-71 years [8,46]. 
Also, the strength of the association between MS and GDF-15 appeared to increase somewhat 
with increasing age (model 2 mean percentage difference = 11.8% [5.73,18.3] for >70 years vs 
7.38% [1.46,13.6] for ≤70 years; p for interaction=0.23), in line with the stronger association of 
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obesity with GDF-15 in middle-aged subjects compared to children [32,47], and perhaps 
reflecting a cumulative exposure to tissue injury and inflammatory states [8,44]. 
Limitations 
Some study limitations should be acknowledged. First, because we used cross-sectional data, we 
cannot assure that MS always preceded the rise in GDF-15 levels. We cannot rule out that GDF-
15 also plays a role in the regulation of food intake and in carbohydrate and lipid metabolism 
[8,9], which might be in turn associated with MS itself. Second, anthropometric techniques can 
be helpful for the assessment of body fat distribution, but they might not be used to make 
inferences on subcutaneous and visceral fat -note that the former may exceed the latter by 
twofold or threefold even in subjects with abdominal obesity- [3,48]. 
Moreover, despite MS and GDF-15 being assessed with standardized procedures and analytical 
techniques, some measurement error is unavoidable, though this would usually bias study results 
towards the null [49]. Also, the self-reported nature of some covariates may not allow to rule out 
residual confounding, even after adjusting the models for several lifestyle and sociodemographic 
variables -notably age, the presumed single strongest predictor of GDF-15 levels [12,30,35]-. 
Finally, some imprecision may have arisen due to the limited sample size, especially in the 
analyses regarding ancillary metabolic biomarkers (n=853). 
Conclusions 
MS was associated with higher GDF-15 levels in older adults, highlighting its potential role as a 
biomarker for the development of diabetes and cardiovascular disease. The main drivers of this 
association were abdominal obesity, hyperglycemia -possibly linked to microvascular disease-, 
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low HDL-cholesterol, and inflammation. Nonetheless, these findings should be confirmed by 
longitudinal studies using, wherever possible, imaging techniques for the assessment of body fat. 
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Table 1. Characteristics of 1938 older adults free of diabetes and cardiovascular disease,a by metabolic syndrome status and its components. 
   Components of metabolic syndrome 
 Metabolic syndrome Waist circumference Fasting glucose Blood pressure Triglycerides HDL-cholesterol 
 No  Yesb Normal  Highc Normal  Highd Normal  Highe Normal  Highf Normal  Lowg 
n  1417 521 1035 903 1480 458 440 1498 1612 326 1557 381 
GDF-15 (pg/ml), geometric mean 
[geometric SD factor] 
1088 [1.50] 1227 [1.53]* 1094 [1.53] 1159 [1.50]* 1105 [1.50] 1188 [1.54]* 1082 [1.50] 1136 [1.52]* 1115 [1.51] 1166 [1.51] 1096 [1.50] 1243 [1.55]* 
Sex, %             
Men 47.6 40.7* 57.8 31.9* 42.8 55.2* 41.1 47.1* 45.4 47.2 47.2 39.6* 
Women 52.4 59.3 42.2 68.1 57.2 44.8 58.9 52.9 54.6 52.8 52.8 60.4 
Age (years) 71.3 [4.22] 71.9 [4.48]* 71.2 [4.11] 71.7 [4.49]* 71.3 [4.27] 71.8 [4.36]* 70.8 [4.22] 71.6 [4.30]* 71.5 [4.25] 71.2 [4.50] 71.3 [4.25] 71.8 [4.44] 
Educational level, %             
Primary or less  61.2 64.9 57.2 67.9* 61.6 64.0 60.2 62.8 62.0 62.9 61.8 63.5 
Secondary  19.5 18.8 22.2 15.9 19.1 20.1 19.8 19.2 18.9 21.5 19.9 16.8 
University  19.3 16.3 20.6 16.2 19.3 15.9 20 18.1 19.1 15.6 18.2 19.7 
Tobacco smoking, %             
Never  54.3 52.6 52.1 55.9 55.8 47.6* 53.2 54.1 54.5 50.9* 53.8 54.3* 
Former  36.6 37.4 37.3 36.2 34.6 43.9 37.3 36.6 37.0 35.6 37.7 33.1 
Current  9.1 10.0 10.6 7.9 9.6 8.5 9.6 9.3 8.5 13.5 8.5 12.6 
Alcohol consumption, %             
Never  17.2 20.9 15.6 21.3* 19.0 15.7* 20 17.7 17.8 20.2 17.1 22.6* 
Former  6.35 5.76 6.76 5.54 6.55 5.02 7.95 5.67 6.33 5.52 5.33 9.71 
Moderateh 53.0 53.6 53.7 52.5 53.3 52.6 50.7 53.9 53.7 50.3 51.9 58.3 
Heavy  23.4 19.8 24.0 20.7 21.1 26.6 21.4 22.8 22.1 23.9 25.6 9.4 
Diet quality (MEDAS) 7.15 [1.67] 7.09 [1.78] 7.12 [1.67] 7.15 [1.74] 7.12 [1.68] 7.19 [1.75] 7.07 [1.63] 7.15 [1.72] 7.17 [1.69] 6.98 [1.74]* 7.18 [1.70] 6.94 [1.68]* 
Energy intake (kcal/day) 1936 [337] 1985 [366]* 1950 [342] 1947 [350] 1924 [333] 2029 [374]* 1915 [337] 1959 [348]* 1939 [345] 1996 [346]* 1954 [346] 1927 [345] 
Light physical activity (min/day) 159 [52.2] 145 [52.8]* 156 [52.1] 153 [53.5] 157 [52.3] 148 [53.7]* 162 [51.5] 153 [53.0]* 157 [52.6] 144 [52.5]* 158 [52.1] 141 [53.2]* 
Moderate-to-vigorous PA (min/day) 65.5 [39.4] 50.3 [34.6]* 67.1 [39.5] 54.8 [36.9]* 61.8 [38.1] 59.9 [40.8] 67.1 [41.2] 59.7 [37.9]* 63.2 [39.4] 52.6 [34.4]* 64.8 [39.8] 47.6 [30.5]* 
Sedentary behavior (min/day) 769 [138] 822 [158]* 774 [152] 794 [137]* 776 [140] 806 [161]* 772 [147] 787 [145]* 775 [139] 823 [170]* 775 [142] 818 [155]* 
MEDAS = Mediterranean Diet Adherence Screener. PA = Physical activity. Values are means [standard deviations] unless otherwise indicated. *P value <0.05 for differences in 
means (Wilcoxon rank-sum) or proportions (Pearson’s chi-squared) across the categories of metabolic syndrome and its components. 
a Participants who had a blood glucose level ≥ 126 mg/dL, had HbA1c levels ≥6.5 %, were treated with antidiabetic drugs, or had a diagnosis of diabetes mellitus or cardiovascular 
disease (myocardial infarction, stroke, or heart failure).  
b ≥3 components of metabolic syndrome. 
c Waist circumference ≥102 cm in men and ≥88 cm in women. d Fasting glucose levels ≥100 mg/dl. e Systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg, 
or treatment with antihypertensive medication. f Triglyceride levels ≥150 mg/dl. g Serum HDL-cholesterol <40 mg/dl in men and <50 mg/dl in women. 
h Moderate drinking: ≤10 g/day in women and ≤20 g/day in men.
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Table 2. Association of metabolic syndrome and its components with GDF-15 in 1938 older adults free of 
diabetes and cardiovascular disease.a 
  
Mean percentage difference in GDF-15 
[95% confidence interval] 
 n  Crude Model 1b Model 2c 
Metabolic syndrome      
No  1417 0 (reference) 0 (reference) 0 (reference) 
Yesd  521 12.7 [8.17,17.5]***  11.4 [7.12,15.8]***  9.34 [5.16,13.7]*** 
Components of metabolic syndrome     
Waist circumference      
Normal  1035 0 (reference) 0 (reference) 0 (reference) 
Highe  903 5.94 [2.10,9.93]**  7.40 [3.63,11.3]***  6.74 [2.97,10.6]*** 
Fasting glucose levels      
Normal  1480 0 (reference) 0 (reference) 0 (reference) 
Highf  458 7.57 [3.00,12.3]***  4.40 [0.21,8.76]*  4.91 [0.77,9.23]* 
Blood pressure      
Normal  440 0 (reference) 0 (reference) 0 (reference) 
Highg  1498 4.99 [0.46,9.72]*  1.64 [-2.48,5.93]  1.49 [-2.55,5.69] 
Triglyceride levels      
Normal  1612 0 (reference) 0 (reference) 0 (reference) 
Highh  326 4.54 [-0.50,9.83]  5.24 [0.50,10.2]*  2.54 [-2.04,7.34] 
Serum HDL cholesterol      
Normal  1557 0 (reference) 0 (reference) 0 (reference) 
Lowi  381 13.4 [8.26,18.7]***  12.6 [7.81,17.5]***  8.13 [3.51,13.0]*** 
*p<0.05. **p<0.01. ***p<0.001.  
a Participants who had a blood glucose level ≥ 126 mg/dL, had HbA1c levels ≥6.5 %, were treated with 
antidiabetic drugs, or had a diagnosis of diabetes mellitus or cardiovascular disease (myocardial infarction, 
stroke, or heart failure).  
b Model 1: Linear regression model adjusted for sex, age, and educational level (primary or less, secondary, 
or university).  
c Model 2: As Model 1 and further adjusted for smoking status (never, former, or current), alcohol 
consumption (never, former, moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet quality 
(Mediterranean Diet Adherence Screener), energy intake (kcal/day), light physical activity (min/day), 
moderate-to-vigorous physical activity (min/day), and sedentary behavior (min/day). 
d ≥3 components of metabolic syndrome. 
e Waist circumference ≥102 cm in men and ≥88 cm in women. f Fasting glucose levels ≥100 mg/dl. g Systolic 
blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 mm Hg, or treatment with antihypertensive 
medication. h Triglyceride levels ≥150 mg/dl. i Serum HDL cholesterol <40 mg/dl in men and <50 mg/dl in 
women. 
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Table 3. Association of ancillary adiposity measures with GDF-15 in 1938 older adults free of 
diabetes and cardiovascular disease.a 
  
Mean percentage difference in GDF-15 
[95% confidence interval] 
 n  Crude Model 1b Model 2c 
Body mass index (kg/m2)      
Categories     
<25  559 0 (reference) 0 (reference) 0 (reference) 
25 to 30  932 -2.39 [-6.55,1.94]  -3.08 [-6.95,0.96]  -2.27 [-6.13,1.74] 
≥30  447 3.30 [-1.89,8.77]  2.90 [-1.96,8.01]  2.38 [-2.47,7.48] 
p for trend  1938 0.220  0.249  0.353 
Hip circumference     
Tertiles d      
1 (lower)  694 0 (reference) 0 (reference) 0 (reference) 
2  681 -1.17 [-5.41,3.26] -1.25 [-5.21,2.88] -0.56 [-4.49,3.53] 
3 (higher) 563 1.77 [-2.82,6.58] 1.55 [-2.74,6.02] 0.77 [-3.50,5.23] 
p for trend  1938 0.448 0.477 0.724 
Waist-to-hip ratio      
Categories     
Normal  462 0 (reference) 0 (reference) 0 (reference) 
High e 1476 11.9 [7.16,16.8]***  8.18 [3.65,12.9]***  7.07 [2.63,11.7]** 
p for trend  1938 <0.001  <0.001  0.002 
*p<0.05. **p<0.01. ***p<0.001.  
a Participants who had blood glucose levels ≥ 126 mg/dL, had HbA1c levels ≥6.5 %, were treated 
with antidiabetic drugs, or had a diagnosis of diabetes mellitus or cardiovascular disease 
(myocardial infarction, stroke, or heart failure).  
b Model 1: Linear regression model adjusted for sex, age, and educational level (primary or less, 
secondary, or university).  
c Model 2: As Model 1 and further adjusted for smoking status (never, former, or current), alcohol 
consumption (never, former, moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet 
quality (Mediterranean Diet Adherence Screener), energy intake (kcal/day), light physical activity 
(min/day), moderate-to-vigorous physical activity (min/day), and sedentary behavior (min/day). 
d Hip circumference tertiles: tertile 1, <= 98 cm in men and <= 99.6 cm in women; tertile 2, 98 to 
104 cm in men and 99.6 to 107 cm in women; tertile 3, >104 cm in men and >107 cm in women.  
e Waist-to-hip ratio ≥0.90 in men and ≥0.85 in women. 
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Table 4. Association of ancillary metabolic biomarkers with GDF-15 in 853 older adults free of 
diabetes and cardiovascular disease.a 
  
Mean percentage difference in GDF-15 
[95% confidence interval] 
 n  Crude Model 1b Model 2c 
HOMA-IR      
Categories     
Normal  478 0 (reference) 0 (reference) 0 (reference) 
High d 375 4.85 [-0.50,10.5]  3.53 [-1.50,8.82]  3.13 [-1.91,8.43] 
p for trend  853 0.076  0.172  0.227 
Glycated hemoglobin (%)      
Categories     
<5.7  512 0 (reference) 0 (reference) 0 (reference) 
5.7 to 6.4  341 2.34 [-2.96,7.93]  0.57 [-4.41,5.80]  -0.05 [-4.94,5.09] 
p for trend  853 0.393  0.826  0.984 
Urine albumin (mg/l)      
Categories     
<10  649 0 (reference) 0 (reference) 0 (reference) 
10 to 20  132 7.56 [0.086,15.6]*  4.76 [-2.20,12.2]  3.42 [-3.40,10.7] 
≥20  72 18.1 [7.56,29.7]***  13.6 [3.87,24.2]**  12.1 [2.57,22.5]* 
p for trend  853 <0.001  0.003  0.010 
High-sensitivity C-reactive protein (mg/l)     
Categories     
<1  391 0 (reference) 0 (reference) 0 (reference) 
1 to 3  248 -1.02 [-6.91,5.24]  -0.53 [-6.14,5.42]  -0.71 [-6.24,5.15] 
>3  214 11.0 [4.09,18.4]**  12.6 [5.96,19.7]***  10.4 [3.89,17.3]** 
p for trend  853 <0.001  <0.001  <0.001 
*p<0.05. **p<0.01. ***p<0.001.  
a Participants who had a blood glucose level ≥ 126 mg/dL, had HbA1c levels ≥6.5 %, were treated with antidiabetic 
drugs, or had a diagnosis of diabetes mellitus or cardiovascular disease (myocardial infarction, stroke, or heart 
failure).  
b Model 1: Linear regression model adjusted for sex, age, and educational level (primary or less, secondary, or 
university).  
c Model 2: As Model 1 and further adjusted for smoking status (never, former, or current), alcohol consumption 
(never, former, moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet quality (Mediterranean Diet 
Adherence Screener), energy intake (kcal/day), light physical activity (min/day), moderate-to-vigorous physical 
activity (min/day), and sedentary behavior (min/day). 
d HOMA-IR ≥ 2.25 in men and ≥ 2.38 in women. 
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Figure 1. Association of metabolic syndrome and its components with GDF-15 in 1938 older adults free of 
diabetes and cardiovascular disease.a 
 
a Participants who had a blood glucose level ≥ 126 mg/dL, had HbA1c levels ≥6.5 %, were treated 
with antidiabetic drugs, or had a diagnosis of diabetes mellitus or cardiovascular disease 
(myocardial infarction, stroke, or heart failure). 
Plotted values are geometric means (95% confidence intervals) obtained from a linear regression 
model adjusted as Model 2 in Table 2: sex, age, educational level (primary or less, secondary, or 
university), smoking status (never, former, or current), alcohol consumption (never, former, 
moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet quality (Mediterranean Diet 
Adherence Screener), energy intake (kcal/day), light physical activity (min/day), moderate-to-
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The restricted cubic spline knots are located at 1-2-3 components for metabolic syndrome, 81-95-
109 cm for waist circumference, 79-91-107 mg/dl for fasting glucose levels, 112-133-158 mm Hg 
for systolic blood pressure, 67-80-94 mm Hg for diastolic blood pressure, 64-99-169 mg/dl for 
triglyceride levels, and 40-54-74 mg/dl for serum HDL-cholesterol levels.
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Supplemental Table 1. Association of metabolic syndrome and its components with GDF-15 in 
2515 older adults. 
  Mean percentage difference [95% confidence interval] 
 n  Crude Model 1a  Model 2b 
Metabolic syndrome      
No  1601 0 (reference) 0 (reference) 0 (reference) 
Yesc  914 28.7 [23.8,33.8]***  27.6 [23.0,32.4]***  24.3 [19.7,29.1]*** 
Components of metabolic syndrome     
Waist circumference      
Normal  1248 0 (reference) 0 (reference) 0 (reference) 
Highd  1267 10.1 [5.92,14.4]***  12.7 [8.57,17.1]***  10.4 [6.25,14.7]*** 
Fasting glucose levels      
Normal  1549 0 (reference) 0 (reference) 0 (reference) 
Highe  966 36.0 [30.9,41.2]***  31.8 [27.0,36.7]***  30.1 [25.5,34.9]*** 
Blood pressure      
Normal  515 0 (reference) 0 (reference) 0 (reference) 
Highf  2000 9.38 [4.26,14.7]***  6.25 [1.52,11.2]**  5.61 [1.01,10.4]* 
Triglyceride levels      
Normal  2021 0 (reference) 0 (reference) 0 (reference) 
Highg  494 14.6 [9.14,20.3]***  15.8 [10.6,21.2]***  12.3 [7.30,17.5]*** 
Serum HDL cholesterol      
Normal  1906 0 (reference) 0 (reference) 0 (reference) 
Lowh  609 25.4 [20.0,31.1]***  25.0 [19.9,30.4]***  19.2 [14.2,24.4]*** 
*p<0.05. **p<0.01. ***p<0.001.  
a Model 1: Linear regression model adjusted for sex, age, and educational level (primary or less, 
secondary, or university).  
b Model 2: As Model 1 and further adjusted for smoking status (never, former, or current), alcohol 
consumption (never, former, moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet 
quality (Mediterranean Diet Adherence Screener), energy intake (kcal/day), light physical activity 
(min/day), moderate-to-vigorous physical activity (min/day), and sedentary behavior (min/day). 
c ≥3 components of metabolic syndrome. 
d Waist circumference ≥102 cm in men and ≥88 cm in women. e Fasting glucose levels ≥100 mg/dl or 
treatment with antidiabetic drugs. f Systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥85 
mm Hg, or treatment with antihypertensive medication. g Triglyceride levels ≥150 mg/dl. h Serum HDL 
cholesterol <40 mg/dl in men and <50 mg/dl in women.  
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Supplemental Table 2. Association of ancillary adiposity measures with GDF-15 in 2515 older 
adults. 
  
Mean percentage difference in GDF-15 
[95% confidence interval] 
 n  Crude Model 1a Model 2b 
Body mass index 
(kg/m2)  
    
Categories     
<25  672 0 (reference) 0 (reference) 0 (reference) 
25 to 30  1184 -0.36 [-4.92,4.41]  -0.91 [-5.22,3.60]  -0.76 [-5.00,3.67] 
≥30  659 9.31 [3.65,15.3]**  9.55 [4.16,15.2]***  6.99 [1.66,12.6]** 
p for trend  2515 <0.001  <0.001  0.007 
Hip circumference     
Tertilesc      
1 (lower)  884 0 (reference) 0 (reference) 0 (reference) 
2  850 -2.70 [-7.13,1.95] -2.25 [-6.48,2.16] -1.92 [-6.08,2.43] 
3 (higher) 781 2.32 [-2.45,7.31] 2.25 [-2.26,6.98] -0.13 [-4.58,4.53] 
p for trend  2515 0.314 0.304 0.981 
Waist-to-hip ratio      
Categories     
Normal  518 0 (reference) 0 (reference) 0 (reference) 
Highd 1997 19.9 [14.3,25.7]***  15.8 [10.5,21.4]***  13.0 [7.85,18.4]*** 
p for trend  2515 <0.001  <0.001  <0.001 
*p<0.05. **p<0.01. ***p<0.001.  
a Model 1: Linear regression model adjusted for sex, age, and educational level (primary or less, 
secondary, or university).  
b Model 2: As Model 1 and further adjusted for smoking status (never, former, or current), alcohol 
consumption (never, former, moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet 
quality (Mediterranean Diet Adherence Screener), energy intake (kcal/day), light physical activity 
(min/day), moderate-to-vigorous physical activity (min/day), and sedentary behavior (min/day). 
c Hip circumference tertiles: tertile 1, <= 98 cm in men and <= 99.6 cm in women; tertile 2, 98 to 
104 cm in men and 99.4 to 107 cm in women; tertile 3, >104 cm in men and >107 cm in women. 
d Waist-to-hip ratio ≥0.90 in men and ≥0.85 in women.  
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Supplemental Table 3. Association of ancillary metabolic biomarkers with GDF-15 in 1080 older 
adults. 
  
Mean percentage difference in GDF-15 
[95% confidence interval] 
 n  Crude Model 1a Model 2b 
HOMA-IR      
Categories     
Normal  532 0 (reference) 0 (reference) 0 (reference) 
High c 548 12.0 [5.97,18.4]***  10.9 [5.22,17.0]***  9.78 [4.09,15.8]*** 
p for trend  1080 <0.001  <0.001  <0.001 
Glycated hemoglobin (%)      
Categories     
<5.7  531 0 (reference) 0 (reference) 0 (reference) 
5.7 to 6.4  423 9.27 [3.32,15.6]**  7.26 [1.67,13.2]*  6.42 [0.94,12.2]* 
≥6.5 126 70.1 [56.2,85.2]***  66.9 [53.9,81.0]***  61.8 [49.2,75.4]*** 
p for trend  1080 <0.001  <0.001  <0.001 
Urine albumin (mg/l)      
Categories     
<10  789 0 (reference) 0 (reference) 0 (reference) 
10 to 20  173 9.71 [1.76,18.3]*  6.58 [-0.87,14.6]  5.65 [-1.63,13.5] 
≥20  118 37.4 [25.7,50.1]***  29.6 [19.0,41.2]***  26.6 [16.4,37.7]*** 
p for trend  1080 <0.001  <0.001  <0.001 
High-sensitivity C-reactive protein (mg/l)     
Categories     
<1  482 0 (reference) 0 (reference) 0 (reference) 
1 to 3  307 -1.98 [-8.27,4.74]  -0.40 [-6.50,6.10]  -0.80 [-6.76,5.54] 
>3  291 15.3 [7.80,23.4]***  17.4 [10.0,25.2]***  14.4 [7.38,22.0]*** 
p for trend  1080 <0.001  <0.001  <0.001 
*p<0.05. **p<0.01. ***p<0.001.  
a Model 1: Linear regression model adjusted for sex, age, and educational level (primary or less, secondary, or 
university).  
b Model 2: As Model 1 and further adjusted for smoking status (never, former, or current), alcohol consumption 
(never, former, moderate [≤10 g/day in women and ≤20 g/day in men], or heavy), diet quality (Mediterranean Diet 
Adherence Screener), energy intake (kcal/day), light physical activity (min/day), moderate-to-vigorous physical 
activity (min/day), and sedentary behavior (min/day). 
c HOMA-IR ≥ 2.25 in men and ≥ 2.38 in women. 
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No data on exposures 
- HOMA-IR (n=1066) 
- HbA1c (n=1075) 
- Urine albumin (n=1064) 




1. ELIGIBLE BUT NOT INCLUDED (total=758) 
No data on GDF-15 (n=684) 
No data on exposures (total=719) 
- Waist circumference (n=454) 
- Hip circumference (n=458) 
- Body mass index (n=453) 
- Fasting glucose levels (n=560) 
- Blood pressure (n=217) 
- Triglyceride levels (n=686) 
- Serum HDL cholesterol (n=686) 
No data on potential confounders (total=488) 
- Educational level (n=2) 
- Alcohol consumption (n=483) 
- Sedentary behavior (n=14) 
- Diet quality (n=483) 
- Energy intake (n=483) 
2. INELIGIBLE (total=577) 
Established diabetes (total=516) 
- Fasting glucose levels ≥126 mg/dL (n=248) 
- HbA1c levels ≥6.5 % (n=127) 
- Treated with antidiabetic drugs (n=400) 
- Previous diagnosis of diabetes (n=463) 
Known cardiovascular disease (total=87) 
- Myocardial infarction (n=27) 
- Stroke (n=26) 
- Heart failure (n=44) 
Secondary analytical sample 
n=853 
Main analytical sample 
n=1938 
